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  Because many inflammatory arthropathies primarily 
involve the synovial tissue, there has been increased interest 
in investigations of the pathologic changes in synovial 
biopsy specimens during the last 2 decades (Reviewed in 
[1]). This development has been stimulated by technical 
advances such as the advent of new methods to obtain 
synovial tissue specimens from actively inflamed joints and 
clinically quiescent joints under local anesthesia, such as 
mini-arthroscopy and ultrasound-guided synovial biopsy, 
and because of the development of new laboratory 
techniques used to analyse the synovial tissue samples. 
Systematic analysis of synovial tissue has lead to the 
identification of key therapeutic targets, such as TNF and IL-
6 as well as many others that are currently being tested. 
  Previous work has also shown that there is a relationship 
between the characteristics of rheumatoid synovial tissue and 
arthritis activity. The importance of evaluation of synovial 
tissue samples after experimental treatment has been 
underscored by the observation that clinical signs and 
symptoms of arthritis are associated with histological signs 
of synovitis after treatment of rheumatoid arthritis patients 
with the monoclonal antibody alemtuzumab, despite 
profound depletion of circulating lymphocytes. Similarly, 
rituximab treatment leads to a rapid and significant decrease 
in synovial B cell numbers in only a subset of rheumatoid 
arthritis patients, whereas circulating B cells are completely 
depleted in nearly all patients. Collectively, there is now 
consistent evidence indicating that analyses of serial biopsy 
samples can be used as a screening method to test new drug 
candidates with high sensitivity to change. The absence of 
changes after treatment would suggest that the therapy is 
probably not effective, even when only relatively small 
numbers of subjects have been tested. In contrast, the 
demonstration of biologic changes in the synovium could 
provide the rationale for larger, placebo-controlled trials. 
Most of the synovial biopsy studies have been performed in 
rheumatoid arthritis patients, but the same approach could be 
used for the evaluation of novel therapies in patients with   
 
 
*Address correspondence to this author at the Division of Clinical 
Immunology & Rheumatology, F4-105, Academic Medical Center, 
University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The 
Netherlands; Tel: +31 20 566 7765; Fax: +31 20 691 9658;  
E-mail: P.P.Tak@amc.uva.nl 
 
§Guest Editor 
ankylosing spondylitis, psoriatic arthritis and other forms of 
spondyloarthritis. 
  The aim of this Special Issue of the Open Rheumatology 
Journal is to provide a state of the art overview of the 
features of the synovium in healthy individuals as well as 
patients with rheumatoid arthritis or different forms of 
spondyloarthritis. In addition, the authors, who are leading 
investigators in this field, describe what is known about the 
synovial tissue response to treatment. 
  In the first Chapter, Dr. Smith describes the normal 
synovium, which refers to the soft tissue lining the spaces of 
diarthrodial joints, tendon sheaths and bursae. It includes the 
continuous surface layer of cells (intimal lining layer) and 
the underlying tissue (synovial sublining). The intimal lining 
layer consists of macrophages and ﬁbroblast-like 
synoviocytes while the synovial sublining includes blood 
and lymphatic vessels, a cellular content of both resident 
ﬁbroblasts and inﬁltrating cells in a collagenous extracellular 
matrix. Together, this structure provides a non-adherent 
surface between tissue elements. Drs. Hitchon and El-
Gabalawy describe in the second Chapter the changes in 
rheumatoid synovial tissue, which is characterized by 
increased vascularity as well intimal lining layer hyperplasia 
and accumulation of macrophages, plasma cells, T cells, B 
cells, dendritic cells, natural killer cells, mast cells and 
neutrophils in the synovial sublining, among other changes. 
The study of serial synovial biopsies, in the context of proof-
of-principle trials, successfully distinguished between 
effective and ineffective treatments in patients with 
rheumatoid arthritis (Sousa et al., Chapter 3). Decreased 
disease activity after effective treatment has consistently 
been associated with a reduction of the number of synovial 
sublining macrophages across different therapies. This 
attractive approach can be used during early drug 
development for screening proposes, supporting which new 
treatments have higher probability to be beneficial in a large 
scale clinical trial. 
  Drs. Appels and Braun emphasize in Chapter 4 the 
importance of the entheses as a site primarily involved in the 
peripheral and axial inflammation found in patients with 
spondyloarthritides and describe the features of the 
synovium in these conditions. The group of spondylo-
arthritides comprise ankylosing spondylitis, psoriatic 
arthritis, reactive arthritis, arthritis associated with chronic 
inflammatory bowel disease and undifferentiated 
spondyloarthritis. Next, Chapter 5 describes the synovial Editorial  The Open Rheumatology Journal, 2011, Volume 5   99 
tissue response to treatment of patients with peripheral 
spondyloarthritis (Paramarta et al.). Although data are 
mainly confined to the effects of TNF inhibition, initial 
studies suggest that the study of serial synovial biopsies 
could also be used in spondyloarthritis to distinguish 
between effective and ineffective treatments. Most studies 
using serial biopsy in spondyloarthritis have been conducted 
in psoriatic arthritis, which is discussed in more detail by 
Drs. Codullo and McInnes in Chapter 6. In this condition, 
serial skin biopsy can be evaluated as well. 
  Collectively, analysis of molecular markers in synovial 
tissue is increasingly used to provide insight into the 
pathogenesis and to provide proof of mechanism during 
early drug development. Tissue specificity is not a problem, 
and examination of serial biopsy samples may be used to 
monitor the response in individual patients and screen for 
interesting biologic effects at the site of inflammation. It can 
be anticipated that future development will include the use of 
more extensive markers of synovial inflammation and joint 
degradation and the use of panels of biomarkers in synovial 
tissue samples. 
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